public expose pt darya-varia laboratoria expose/materi public expose...  public expose pt...

Download PUBLIC EXPOSE PT DARYA-VARIA LABORATORIA Expose/Materi Public Expose...  PUBLIC EXPOSE PT DARYA-VARIA

Post on 06-Mar-2019

219 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

PUBLIC EXPOSE

PT DARYA-VARIA LABORATORIA TBKHotel Fairmont, 7 Mei 2018

Jakarta1

Topik / Topics :1. Tinjauan Pasar

Market Overview

2. Sekilas tentang DVLDVL at a Glance

3. Tinjauan Bisnis DVL Tahun 2017DVL Business Overview FY 2017

4. Kinerja DVL Kuartal 1-2018 DVL Performance 1st Q-2018 2

TINJAUAN

PASARM A R K E T O V E R V I E W

3

Sebagaimana dilaporkan oleh Badan Pusat Statistik (BPS), 2017: Pendapatan Domestik Bruto (PDB) Rp13.588,8 triliun PDB per kapita sebesar Rp51,89 juta atau USD 3.876,8 Komponen konsumsi rumah tangga berkontribusi 56,13% Belanja pemerintah berkontribusi 9,10%

As reported by Central Statistics Agency (BPS), 2017: Gross Domestic Product (GDP) Rp13,588.8 trillion GDP per capita Rp51.89 million or USD 3,876.8. Household consumption contributed 56.13% Government consumption 9.10%

Perekonomian Indonesia tumbuh 5,07%

Indonesias economy grew by 5.07%

4.3 4.3

3.53.6

3.4

3.2

5.0

4.8

5.0 5.1

2.5

3

3.5

4

4.5

5

5.5

6

6.5

7

2014 2015 2016 2017

Emerging market World Indonesia

5,07

Kondisi UmumGeneral Conditions

4

Kondisi UmumGeneral Conditions

Stabilitas makroekonomi terjaga dengan baik:- inflasi 3,61%- nilai tukar Rp13.548 per dolar AS

Macroeconomic stability was well-maintained:- inflation at 3.61%- exchange rate closed 2017 at Rp13.548 to the US dollar

5

Semakin dekatnya penerapan untuk kriteria halalImpending implementation of halal compliance

Peningkatan cakupan Program Jaminan Kesehatan Nasional (JKN) yang diselenggarakan BPJS Kesehatan hingga 70% penduduk IndonesiaNational Health Insurance (NHI) program by BPJS Kesehatan, increased its coverage to about 70% of Indonesian citizens

Pengetatan peraturan oleh Badan Pengawas Obat dan Makanan(BPOM) NasionalTightened regulations by the National Agency of Food & Drug Control (BPOM)

Perkembangan yang mempengaruhi industri farmasi:Developments that impacted the pharmaceutical industry:

Kondisi UmumGeneral Conditions

6

SEKILAS

TENTANG DVL

D V L AT A G L A N C E

7

8

9

Segmen Bisnis UtamaMain Business Segments

Bisnis Obat ResepPrescription Business

Bisnis Consumer HealthConsumer Health Business

Bisnis Ekspor& Jasa Toll Manufacturing

Export & Toll Manufacturing Business

10

Fasilitas ProduksiProduction Facilities

Citeureup, BogorProduk Steril & Padat

Sterile & Solid

Gunung Putri, BogorKapsul Lunak, Cairan, KosmetikSoft Capsule, Liquid, Cosmetic

11

IKHTISAR

DVLD V L H I G H L I G H T S

12

Peluncuran Produk BaruNew Products Launch

MARCH 2017DIPITENZ

APRIL 2017IAL SYSTEM

OCTOBER 2017PROTEZID

NOVEMBER 2017ESOZID 13

Kegiatan PemasaranMarketing Activities

Scientific Seminars

Medical Science Centre

PR & On-Ground Activation

Digital Marketing

14

TINJAUAN BISNIS

DVL TAHUN 2017

D V L B U S I N E S S O V E R V I E W

F Y 2 0 1 7

15

Kinerja DVL Tahun 2017DVL Performance FY 2017

Penjualan Bersih (Net Sales)(Miliar/Billion Rupiah)

Pertumbuhan(Growth)

Bisnis Obat Resep(Prescription Business)

537 12%

Bisnis Kesehatan Konsumen(Consumer Health Business)

746 14%

Bisnis Ekspor & Jasa Toll Manufacturing(Export & Toll Manufacturing Business)

292 (8%)

Jumlah Penjualan Bersih / Total Net Sales 1.575 8,6%

16

LAPORAN LABA RUGI STATEMENT OF PROFIT OR LOSS

Uraian(dalam miliar Rupiah)

2017 2016% Pertumbuhan

% GrowthDescription

(in billion Rupiah)

Laba Bruto 894 801 12% Gross Income

Laba Usaha 220 204 8% Operating Income

Laba Bersih 162 152 7% Net Income

Marjin Laba Bersih 10% 10% - Net Income Margin

Laba bersih per saham(Rupiah penuh)

145 136 7%Net Income per Share (full rupiah)

17

Uraian(dalam miliar Rupiah)

2017 2016Increase/

(Decrease)Description

(in billion Rupiah)

Total Aset 1.641 1.531 7% Total Assets

Aset Lancar 1.176 1.069 10% Current Assets

Total Liabilitas 525 452 16% Total Liabilities

Ekuitas 1.116 1.080 3% Equity

LAPORAN POSISI KEUANGAN STATEMENT OF FINANCIAL POSITION

18

LAPORAN ARUS KASSTATEMENT OF CASH FLOWS

Uraian(dalam miliar Rupiah)

2017 2016Increase/ Decrease

Description (in billion Rupiah)

Arus kas dari operasional

231 187 23%Cash flows from operations

Arus kas untuk aktivitas investasi

(41) (197) (79%)Cash flows used in investing activities

Arus kas untuk aktivitas pendanaan

(112) (39) 187%Cash flows used in financing activities

19

D V L P E R F O R M A N C E

1 s t Q - 2 0 1 8

KINERJA DVL

KUARTAL 1-2018

20

Kinerja Kuartal 1-2018Q1 2018 Performance

I. Total Penjualan Bersih DVL sebesar Rp 430 miliar- DVL tumbuh sebesar 8%

II. Apa yang mendukung kinerja bisnis?- Pertumbuhan Bisnis Obat Resep +20%- Pertumbuhan Ekspor dan Jasa Toll

Manufacturing +22%

III. Tantangan bisnis

- Menurunnya industri farmasi

- Consumer Health -7%

I. Total DVL Net Sales at Rp 430 bio- DVL grew by 8%

II. What drove the business?

- Prescription Business +20% growth

- Export and Toll Manufacturing +22% growth

III. Business challenges

- Pharma industry in declined

- Consumer Health -7%

IV. Keuangan :

- Laba Bruto, Laba Usaha & Laba Bersih DVL

tetap terjaga

IV. Financials :

- DVL Gross Income, Operating Income &

Net Profit are on track

V. Program Sampai Dengan Akhir Tahun yang

terencanaV. Balance Year Program in place

21

SESI

TANYA JAWABQ U E S T I O N S A N D A N S W E R S

D V L P U B L I C E X P O S E

22

23

Recommended

View more >